ClinicalTrials.gg
Status unknownNCT03353285Updated Jan 18, 2018

Effect of Follicle Flushing on Oocyte Fertilization Rate

An observational study in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-01-18.

Sponsored by Eugonia · Observational

How we know

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Infertility by Eugonia — none open to participants now, none under way, none of them phase 3. Infertility · Eugonia.

Started
2017
with 1 other
Observational
3 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Infertility by Eugonia, this one is one of 2 that started in 2017, is one of 3 observational ones, and was the 10th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 13 studies in Infertility by Eugonia is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Infertility by Eugonia as a file.
02

Study summary

The purpose of this study is to investigate the impact of follicular flushing on fertilization rate in women undergoing IVF treatment

Read the detailed description

This will be a prospective observational study on the effect of follicular flushing on fertilization rate in women undergoing IVF treatment.

Oocytes from each woman will be allocated to one of three groups, depending on the aspirate or flush they are recovered from:

Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing) Group II= egg retrieved in the 1st-2nd flush Group III= egg retrieved in the 3rd-5th flush

development and utilization. Pregnancy rates will be reported as a surrogate outcome.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Women undergoing IVF treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Up to 40 years old
  • Both ovaries present
  • Triggering final oocyte maturation using hCG or GnRH agonist

Exclusion criteria

Exclusion Criteria:

  • Egg donation
  • PGD cases
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group I

    Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)

    Procedure: intracytoplasmic sperm injection (ICSI)

  • Group II

    Group II= egg retrieved in the 1st-2nd flush

    Procedure: intracytoplasmic sperm injection (ICSI)

  • Group III

    Group III= egg retrieved in the 3rd-5th flush

    Procedure: intracytoplasmic sperm injection (ICSI)

Interventions

  • Procedureintracytoplasmic sperm injection (ICSI)

    All eggs will be fertilized by ICSI

06

What researchers measure

Primary outcomes

  1. Fertilization rate

    Number of fertilized eggs per oocyte retrieved

    Time frame: Day 1 post oocyte retrieval

Secondary outcomes

  1. Maturation rate

    Number of mature (MII) eggs per oocyte retrieved

    Time frame: Day of oocyte retrieval

  2. Good quality embryos

    Number of good quality embryos on Day 2

    Time frame: Day 2 post oocyte retrieval

  3. Blastocyst formation rate

    Number of blastocysts on Day 5 per fertilized egg

    Time frame: Day 5 post oocyte retrieval

07

Study locations

1 of 1 sites recruiting
  • Eugonia
    Athens, 11528, Greece
    Recruiting
08

References and documents

Publications

  • von Horn K, Depenbusch M, Schultze-Mosgau A, Griesinger G. Randomized, open trial comparing a modified double-lumen needle follicular flushing system with a single-lumen aspiration needle in IVF patients with poor ovarian response. Hum Reprod. 2017 Apr 1;32(4):832-835. doi: 10.1093/humrep/dex019. PubMed 28333185 ↗
  • Franasiak JM. Follicular flushing: time to look elsewhere to improve in vitro fertilisation outcomes? BJOG. 2017 Jul;124(8):1197. doi: 10.1111/1471-0528.14628. No abstract available. PubMed 28276189 ↗
  • Roque M, Sampaio M, Geber S. Follicular flushing during oocyte retrieval: a systematic review and meta-analysis. J Assist Reprod Genet. 2012 Nov;29(11):1249-54. doi: 10.1007/s10815-012-9869-9. Epub 2012 Oct 13. PubMed 23065177 ↗

Individual participant data

Plan to share: Undecided — undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Jan 2018, 2 months after the start.

Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's planned 2 months is below that.

Counting every sponsor, half of 240 studies reached it within 39 months; a quarter within 16 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Nov 27, 2017
StartActual
Nov 27, 2017
Primary completionEst.
Jan 31, 2018
CompletionEst.
Jun 1, 2018
Last update
Jan 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03353285
Lead sponsor
Eugonia
Responsible party
Sponsor
First posted
Nov 27, 2017
Start date
Nov 27, 2017
Primary completion
Jan 31, 2018 (estimated)
Completion
Jun 1, 2018 (estimated)
Last update
Jan 18, 2018

Study contacts

Tryfon G Lainas, PhD
Contact
tlainas@eugonia.com.gr
00302107236333
George T Lainas, MD
Contact
ggslns@gmail.com
00302107236333
Tryfon G Lainas, Phd
study director · Eugonia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion